Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes View HTML
Toggle Summary Radius Presents Positive Phase I Data for Investigational Drug RAD1901 at the San Antonio Breast Cancer Symposium (SABCS) 2016
  -3 patients had confirmed partial responses by RECIST criteria from ongoing Phase I studies with RAD1901 in patients with advanced estrogen receptor positive breast cancer- -In the Phase 1 dose escalation and expansion study, 14 heavily pretreated patients remained on RAD1901 for equal to or
View HTML
Toggle Summary Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection
Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection CAMBRIDGE, MA--(Marketwire - Jan 7, 2013) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, is
View HTML
Toggle Summary Radius to Host Investor Day on June 8, 2018
Advancing Treatment Care for Osteoporosis
View HTML
Toggle Summary Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy
Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy CAMBRIDGE, MA--(Marketwire - Dec 5, 2011) - C. Richard Lyttle retires as President and CEO and will serve as interim CSO Kurt Graves
View HTML
Toggle Summary Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis View HTML
Toggle Summary Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis
Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis Cambridge, Mass., December 20, 2012 – Radius Health , Inc. (“Radius”) and 3M Drug Delivery Systems are pleased to announce an exclusive partnership
View HTML
Toggle Summary Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis View HTML
Toggle Summary Sean Murphy joins Radius Health Board of Directors
WALTHAM, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect. Sean has several decades of experience in the industry across pharmaceuticals,
View HTML
Toggle Summary The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study of the Investigational Drug Abaloparatide in Postmenopausal Women With Osteoporosis
-- Multi-center, multi-national, double-blind, placebo-controlled trial in which postmenopausal women were randomized to receive 24-weeks of treatment with either daily subcutaneous injections of placebo, the investigational drug abaloparatide 20, 40 or 80-μg, or teriparatide 20-μg.
View HTML